Drug Type Autologous CAR-T |
Synonyms CX-804, CX804 |
Target |
Action antagonists |
Mechanism L1CAM antagonists(L1 cell adhesion molecule antagonists), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ovarian Cancer | Preclinical | South Korea | 04 Apr 2023 | |
| Ovarian Cancer | Preclinical | South Korea | 04 Apr 2023 | |
| Stomach Cancer | Preclinical | South Korea | 04 Apr 2023 | |
| Stomach Cancer | Preclinical | South Korea | 04 Apr 2023 | |
| Lung Cancer | Preclinical | South Korea | - | |
| Neuroblastoma | Preclinical | South Korea | - |





